[go: up one dir, main page]

FR2947271B1 - Nouveaux composes anticancereux - Google Patents

Nouveaux composes anticancereux

Info

Publication number
FR2947271B1
FR2947271B1 FR0905651A FR0905651A FR2947271B1 FR 2947271 B1 FR2947271 B1 FR 2947271B1 FR 0905651 A FR0905651 A FR 0905651A FR 0905651 A FR0905651 A FR 0905651A FR 2947271 B1 FR2947271 B1 FR 2947271B1
Authority
FR
France
Prior art keywords
anticancer compounds
new anticancer
new
compounds
anticancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0905651A
Other languages
English (en)
Other versions
FR2947271A1 (fr
Inventor
Alain Commercon
Herve Bouchard
Jidong Zhang
Marie Priscille Brun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41611078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2947271(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR0905651A priority Critical patent/FR2947271B1/fr
Priority to PCT/FR2010/050986 priority patent/WO2011001052A1/fr
Priority to MX2011013764A priority patent/MX2011013764A/es
Priority to MYPI2011006289A priority patent/MY156684A/en
Priority to EP10728799A priority patent/EP2448929A1/fr
Priority to CA2766762A priority patent/CA2766762C/fr
Priority to JP2012518108A priority patent/JP5746692B2/ja
Priority to KR1020117031276A priority patent/KR101770584B1/ko
Priority to SG10201607595WA priority patent/SG10201607595WA/en
Priority to BRPI1015131-1A priority patent/BRPI1015131A2/pt
Priority to PE2011002178A priority patent/PE20121031A1/es
Priority to NZ597136A priority patent/NZ597136A/en
Priority to UAA201200825A priority patent/UA108473C2/uk
Priority to AU2010267917A priority patent/AU2010267917B9/en
Priority to CN201080038575.2A priority patent/CN102482238B/zh
Priority to EA201270096A priority patent/EA024627B1/ru
Priority to MA34580A priority patent/MA33465B1/fr
Priority to SG2011097193A priority patent/SG177419A1/en
Priority to ARP100102290A priority patent/AR078131A1/es
Priority to TW099121094A priority patent/TW201110986A/zh
Priority to UY0001032745A priority patent/UY32745A/es
Publication of FR2947271A1 publication Critical patent/FR2947271A1/fr
Priority to DO2011000376A priority patent/DOP2011000376A/es
Priority to CR20110670A priority patent/CR20110670A/es
Priority to SV2011004086A priority patent/SV2011004086A/es
Priority to NI201100219A priority patent/NI201100219A/es
Priority to CL2011003229A priority patent/CL2011003229A1/es
Priority to US13/331,259 priority patent/US8952147B2/en
Priority to ZA2011/09537A priority patent/ZA201109537B/en
Priority to IL217208A priority patent/IL217208A/en
Priority to EC2011011553A priority patent/ECSP11011553A/es
Priority to HN2011003414A priority patent/HN2011003414A/es
Priority to CO11180696A priority patent/CO6430462A2/es
Publication of FR2947271B1 publication Critical patent/FR2947271B1/fr
Application granted granted Critical
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/08—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and more than one oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D245/06—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
FR0905651A 2009-06-29 2009-11-25 Nouveaux composes anticancereux Expired - Fee Related FR2947271B1 (fr)

Priority Applications (32)

Application Number Priority Date Filing Date Title
FR0905651A FR2947271B1 (fr) 2009-06-29 2009-11-25 Nouveaux composes anticancereux
MA34580A MA33465B1 (fr) 2009-06-29 2010-05-20 Nouveaux conjugues, leur preparation et leur application en therapeutique
MX2011013764A MX2011013764A (es) 2009-06-29 2010-05-20 Nuevos conjugados, su preparacion y su uso terapeutica.
MYPI2011006289A MY156684A (en) 2009-06-29 2010-05-20 Novel conjugates, preparation thereof, and therapeutic use thereof
EP10728799A EP2448929A1 (fr) 2009-06-29 2010-05-20 Nouveaux conjugues, leur preparation et leur application en therapeutique
CA2766762A CA2766762C (fr) 2009-06-29 2010-05-20 Nouveaux conjugues, leur preparation et leur application en therapeutique
JP2012518108A JP5746692B2 (ja) 2009-06-29 2010-05-20 新規コンジュゲート、これらの調製およびこれらの治療用途
KR1020117031276A KR101770584B1 (ko) 2009-06-29 2010-05-20 신규 접합체, 그의 제조법, 및 그의 치료 용도
SG10201607595WA SG10201607595WA (en) 2009-06-29 2010-05-20 Novel conjugates, preparation thereof, and therapeutic use thereof
BRPI1015131-1A BRPI1015131A2 (pt) 2009-06-29 2010-05-20 conjugados, o respectivo preparo e a respectiva aplicação em terapêutica
PE2011002178A PE20121031A1 (es) 2009-06-29 2010-05-20 Nuevos conjugados, su preparacion y su aplicacion terapeutica
NZ597136A NZ597136A (en) 2009-06-29 2010-05-20 Novel conjugates, preparation thereof, and therapeutic use thereof
UAA201200825A UA108473C2 (uk) 2009-06-29 2010-05-20 Кон'югати, їхнє одержання і застосування в терапії
AU2010267917A AU2010267917B9 (en) 2009-06-29 2010-05-20 Novel conjugates, preparation thereof, and therapeutic use thereof
CN201080038575.2A CN102482238B (zh) 2009-06-29 2010-05-20 缀合物、其制备方法及其治疗用途
EA201270096A EA024627B1 (ru) 2009-06-29 2010-05-20 Производные криптофицина и его конъюгаты, их получение и применение в терапии
PCT/FR2010/050986 WO2011001052A1 (fr) 2009-06-29 2010-05-20 Nouveaux conjugues, leur preparation et leur application en therapeutique
SG2011097193A SG177419A1 (en) 2009-06-29 2010-05-20 Novel conjugates, preparation thereof, and therapeutic use thereof
ARP100102290A AR078131A1 (es) 2009-06-29 2010-06-28 Conjugados su preparacion y su aplicacion terapeutica
TW099121094A TW201110986A (en) 2009-06-29 2010-06-28 Novel conjugates, preparation thereof and therapeutic use thereof
UY0001032745A UY32745A (es) 2009-06-29 2010-06-29 Nuevos conjugados de criptoficinas, su preparacion y su aplicacion terapeutica
DO2011000376A DOP2011000376A (es) 2009-06-29 2011-12-05 Nuevos conjugados, su preparacion y su aplicacion en terapeutica
CR20110670A CR20110670A (es) 2009-06-29 2011-12-13 Nuevos conjugados, su preparación y su aplicación terapéutica
SV2011004086A SV2011004086A (es) 2009-06-29 2011-12-15 Nuevos conjugados,su preparacion y su aplicacion terapeutica
NI201100219A NI201100219A (es) 2009-06-29 2011-12-19 Nuevos conjugados, su preparación y su aplicación terapéutica.
US13/331,259 US8952147B2 (en) 2009-06-29 2011-12-20 Conjugates, preparation thereof, and therapeutic use thereof
CL2011003229A CL2011003229A1 (es) 2009-06-29 2011-12-20 Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
ZA2011/09537A ZA201109537B (en) 2009-06-29 2011-12-23 Novel conjugates, preparation thereof,and therapeutic use thereof
EC2011011553A ECSP11011553A (es) 2009-06-29 2011-12-26 Nuevos conjugados, su preparación y su aplicación terapéutica
IL217208A IL217208A (en) 2009-06-29 2011-12-26 History of cryptophycin, critophycin conjugates, processes for their preparation, and their use as anticancer agents
HN2011003414A HN2011003414A (es) 2009-06-29 2011-12-28 Nuevos conjugados, su preparacion y su aplicacion terapeutica
CO11180696A CO6430462A2 (es) 2009-06-29 2011-12-29 Nuevos conjugados, su preparación y su aplicación terapéutica

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0903170A FR2947269B1 (fr) 2009-06-29 2009-06-29 Nouveaux composes anticancereux
FR0905651A FR2947271B1 (fr) 2009-06-29 2009-11-25 Nouveaux composes anticancereux

Publications (2)

Publication Number Publication Date
FR2947271A1 FR2947271A1 (fr) 2010-12-31
FR2947271B1 true FR2947271B1 (fr) 2013-04-05

Family

ID=41611078

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0903170A Expired - Fee Related FR2947269B1 (fr) 2009-06-29 2009-06-29 Nouveaux composes anticancereux
FR0905651A Expired - Fee Related FR2947271B1 (fr) 2009-06-29 2009-11-25 Nouveaux composes anticancereux

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0903170A Expired - Fee Related FR2947269B1 (fr) 2009-06-29 2009-06-29 Nouveaux composes anticancereux

Country Status (30)

Country Link
US (1) US8952147B2 (fr)
EP (1) EP2448929A1 (fr)
JP (1) JP5746692B2 (fr)
KR (1) KR101770584B1 (fr)
CN (1) CN102482238B (fr)
AR (1) AR078131A1 (fr)
BR (1) BRPI1015131A2 (fr)
CA (1) CA2766762C (fr)
CL (1) CL2011003229A1 (fr)
CO (1) CO6430462A2 (fr)
CR (1) CR20110670A (fr)
DO (1) DOP2011000376A (fr)
EA (1) EA024627B1 (fr)
EC (1) ECSP11011553A (fr)
FR (2) FR2947269B1 (fr)
HN (1) HN2011003414A (fr)
IL (1) IL217208A (fr)
MA (1) MA33465B1 (fr)
MX (1) MX2011013764A (fr)
MY (1) MY156684A (fr)
NI (1) NI201100219A (fr)
NZ (1) NZ597136A (fr)
PE (1) PE20121031A1 (fr)
SG (2) SG177419A1 (fr)
SV (1) SV2011004086A (fr)
TN (1) TN2011000636A1 (fr)
TW (1) TW201110986A (fr)
UY (1) UY32745A (fr)
WO (1) WO2011001052A1 (fr)
ZA (1) ZA201109537B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2893252C (fr) 2005-08-24 2018-05-29 Immunogen, Inc. Procede de preparation de conjugues maytansinoides-anticorps
ME03479B (fr) 2009-06-03 2020-01-20 Immunogen Inc Procédés de conjugaison
HRP20140754T2 (hr) 2009-06-29 2015-07-17 Incyte Corporation Pirimidinoni kao inhibitori pi3k
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011130342A1 (fr) 2010-04-14 2011-10-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de ρi3κδ
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012087881A1 (fr) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
WO2012125629A1 (fr) 2011-03-14 2012-09-20 Incyte Corporation Dérivés diamino-pyrimidines et diamino-pyridines substituées en tant qu'inhibiteurs de pi3k
WO2012135009A1 (fr) 2011-03-25 2012-10-04 Incyte Corporation Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k
ME03353B (fr) 2011-03-29 2019-10-20 Immunogen Inc Préparation de conjugués de maytansinoïde anticorps par procédé en une étape
LT3196202T (lt) 2011-09-02 2019-07-10 Incyte Holdings Corporation Heterociklilaminai, kaip pi3k slopikliai
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AU2013326881B2 (en) 2012-10-04 2018-08-02 Immunogen, Inc. Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates
CN105593238B (zh) 2013-07-11 2020-09-08 诺华股份有限公司 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
PT3189056T (pt) * 2014-09-03 2020-09-04 Immunogen Inc Derivados citotóxicos de benzodiazepina
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
CN117736209A (zh) 2015-02-27 2024-03-22 因赛特控股公司 Pi3k抑制剂的盐及其制备方法
EP3069734A1 (fr) * 2015-03-17 2016-09-21 Exiris S.r.l. Conjugués anticorps-médicament à base de cryptophycine avec de nouveaux lieurs auto-immolateurs
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Formes cristallines d'un inhibiteur de pi3k
TWI660741B (zh) 2015-11-03 2019-06-01 財團法人工業技術研究院 抗體藥物複合物及其製造方法
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
WO2017136769A1 (fr) * 2016-02-04 2017-08-10 Eisai R&D Management Co., Ltd. Conjugués peptides-médicaments
KR102345175B1 (ko) 2016-11-14 2021-12-31 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
WO2018178277A1 (fr) 2017-03-29 2018-10-04 Avicenna Oncology Gmbh Nouveaux dérivés d'isocombrétaquinoléine cytotoxique ciblés et leurs conjugués
TN2019000303A1 (en) * 2017-05-10 2021-05-07 Sanofi Sa Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation
EP3665161B1 (fr) 2017-08-09 2023-09-27 Helmholtz-Zentrum für Infektionsforschung GmbH Nouveaux dérivés de ratjadone cytotoxiques ciblés et leurs conjugués
AU2018389100B2 (en) * 2017-12-22 2025-02-27 Cornell University 18F-labeled peptide ligands useful in PET and Cerenkov luminescene imaging
PE20211208A1 (es) 2018-06-01 2021-07-05 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
JP2021533200A (ja) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
FR3085952B1 (fr) 2018-09-17 2020-10-30 Centre Nat Rech Scient Conjugue anticorps-medicament comprenant des derives de quinoline
JP2022549971A (ja) * 2019-09-30 2022-11-29 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン クリプトフィシン抗がん剤の生体触媒合成
EP4046996A1 (fr) 2021-02-19 2022-08-24 Universität Bielefeld Composés de cryptophycine et leurs conjugués
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
EP4366784A1 (fr) 2021-07-09 2024-05-15 Dyne Therapeutics, Inc. Complexes ciblant le muscle et formulations de traitement de dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
KR20240082398A (ko) 2021-10-07 2024-06-10 사노피 이미다조[4,5-c]퀴놀린-4-아민 화합물 및 이의 접합체, 이들의 제조 및 이들의 치료 응용
KR20250004770A (ko) 2022-04-15 2025-01-08 다인 세라퓨틱스, 인크. 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
WO2025031923A1 (fr) 2023-08-04 2025-02-13 Sanofi Composés imidazo[4,5-d]pyridazine et conjugués de ceux-ci, leur préparation et leurs utilisations thérapeutiques

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2719170A (en) 1954-07-28 1955-09-27 Du Pont Alkyl omega-carboxyalkyl disulfides and their lower alkyl esters
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
FI913049A0 (fi) 1988-12-22 1991-06-20 Xoma Corp Foerhindrande kopplingsmedel och foerfaranden.
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2056039A1 (fr) 1991-01-22 1992-07-23 Philip L. Fuchs Analogues de carbacycline
GEP20002206B (en) 1995-03-07 2000-08-25 Wane State Univ Cryptophycins, Method for its Production, Pharmaceutical Composition on Their basis and Use
YU10899A (sh) * 1996-08-30 2002-03-18 Eli Lilli And Company Farmaceutska jedinjenja
IL142565A0 (en) 1998-10-16 2002-03-10 Lilly Co Eli Stereoselective process for producing antineoplastic agents
WO2000034252A2 (fr) 1998-12-07 2000-06-15 Eli Lilly And Company Procede de crotylboration permettant de produire des composes de cryptophycine
WO2003043583A2 (fr) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Traitement des troubles immunologiques au moyen des anticorps anti-cd30
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
JP2006500364A (ja) 2002-08-16 2006-01-05 イムノージェン インコーポレーテッド 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
WO2004043344A2 (fr) 2002-11-07 2004-05-27 Immunogen, Inc. Anticorps anti-cd33 et methode de traitement de la leucemie myeloide aigue a l'aide dudit anticorps
PL1651162T3 (pl) 2003-05-20 2016-04-29 Immunogen Inc Maitansynoidy w leczeniu nowotworów
ATE496944T1 (de) 2003-07-21 2011-02-15 Immunogen Inc Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
TW200630106A (en) 2004-10-08 2006-09-01 Wyeth Corp Immunotherapy of autoimmune disorders
EP1669358A1 (fr) 2004-12-07 2006-06-14 Aventis Pharma S.A. Agents cytotoxiques comprenant des nouveau taxanes
WO2006062779A2 (fr) * 2004-12-09 2006-06-15 Centocor, Inc. Immunoconjugues anti-integrines, methodes et applications
GB2438982A (en) 2004-12-22 2007-12-12 Ambrx Inc Compostions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2006096754A2 (fr) 2005-03-07 2006-09-14 Archemix Corp. Aptameres stabilises d'apsm et leur utilisation comme agents therapeutiques contre le cancer de la prostate
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
DK1813614T3 (da) 2006-01-25 2012-01-23 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater
EP1832577A1 (fr) 2006-03-07 2007-09-12 Sanofi-Aventis Promédicament amélioré d'analogues de CC-1065
EP2010475A2 (fr) 2006-04-27 2009-01-07 Intezyne Technologies Incorporated Poly(éthylène glycol) contenant des groupes amino-protecteurs acides-labiles et leurs utilisations
EP1864682A1 (fr) 2006-06-09 2007-12-12 Sanofi-Aventis Dérivés de la Leptomycine
CN101622276B (zh) 2006-07-18 2015-04-22 赛诺菲-安万特 用于治疗癌症的抗epha2的拮抗抗体
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
EP3569251A1 (fr) * 2007-06-25 2019-11-20 Endocyte, Inc. Conjugués contenant des lieurs espaceurs hydrophiles
DK2019104T3 (da) 2007-07-19 2013-12-16 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater, og terapeutisk anvendelse deraf
EP2185188B1 (fr) 2007-08-22 2014-08-06 Medarex, L.L.C. Attachement spécifique d'un site de médicaments ou autres agents à des anticorps synthétisés par génie génétique avec des extensions c-terminales
DK2276509T3 (en) 2008-04-11 2016-09-19 Seattle Genetics Inc DETECTION AND TREATMENT OF CANCER IN PANCREAS, ovarian and other cancers
CN102076717B (zh) 2008-04-30 2016-02-03 伊缪诺金公司 交联剂和它们的用途
BRPI0911442A2 (pt) 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
WO2010014812A2 (fr) 2008-07-30 2010-02-04 The Research Foundation Of State University Of New York Compositions peptidiques et procédés d’utilisation associés

Also Published As

Publication number Publication date
NZ597136A (en) 2014-04-30
PE20121031A1 (es) 2012-08-17
JP2012531459A (ja) 2012-12-10
US20120225089A1 (en) 2012-09-06
FR2947269A1 (fr) 2010-12-31
TN2011000636A1 (fr) 2013-05-24
SG177419A1 (en) 2012-02-28
MA33465B1 (fr) 2012-07-03
EA024627B1 (ru) 2016-10-31
SG10201607595WA (en) 2016-11-29
FR2947269B1 (fr) 2013-01-18
AR078131A1 (es) 2011-10-19
BRPI1015131A2 (pt) 2018-12-04
WO2011001052A1 (fr) 2011-01-06
KR101770584B1 (ko) 2017-08-24
CA2766762A1 (fr) 2011-01-06
HN2011003414A (es) 2014-11-10
EP2448929A1 (fr) 2012-05-09
UY32745A (es) 2011-01-31
IL217208A0 (en) 2012-03-01
US8952147B2 (en) 2015-02-10
MY156684A (en) 2016-03-15
SV2011004086A (es) 2012-05-08
JP5746692B2 (ja) 2015-07-08
DOP2011000376A (es) 2012-01-15
IL217208A (en) 2016-02-29
ZA201109537B (en) 2013-03-27
CR20110670A (es) 2012-02-09
AU2010267917B2 (en) 2016-03-17
AU2010267917A1 (en) 2012-02-02
CN102482238B (zh) 2015-08-12
KR20120101981A (ko) 2012-09-17
FR2947271A1 (fr) 2010-12-31
ECSP11011553A (es) 2012-01-31
TW201110986A (en) 2011-04-01
CO6430462A2 (es) 2012-04-30
CL2011003229A1 (es) 2012-06-29
CA2766762C (fr) 2017-06-20
CN102482238A (zh) 2012-05-30
EA201270096A1 (ru) 2012-07-30
NI201100219A (es) 2012-05-23
MX2011013764A (es) 2012-05-22

Similar Documents

Publication Publication Date Title
HUS2300018I1 (hu) Rákellenes hatású kinoli-8-szulfonamid-származékok
FR2947269B1 (fr) Nouveaux composes anticancereux
FR16C0005I2 (fr) Composes antiviraux
HRP20181221T1 (hr) Poboljšani lipidni pripravak
DE112010002949A5 (de) Kupplungstastpunkte
EP2406768A4 (fr) Structure de délivrance
BRPI1008827A2 (pt) deisobutenizador
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
DE112009005323A5 (de) Hebelarmprüfmaschine
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BRPI1008070A2 (pt) tricianoboratos
BR112012004964A2 (pt) girocóptero
DK3128286T3 (da) Kombineret fyrværkeri
EP2508411A4 (fr) Structure
PL2488157T3 (pl) Ulepszone preparaty
DK2422104T3 (da) Centrifugalkobling
EP2445917A4 (fr) Composes photolabiles
DE112010003255A5 (de) Fördergutverteiler
BRPI1010159A2 (pt) bistuti
ES1070429Y (es) Traspaleta mejorada
BR112012009784A2 (pt) composto benzazepínico
FR2945807B1 (fr) Nouveaux composes anticancereux
EP2632916A4 (fr) Nouveaux agents anticancéreux
PT2546255T (pt) Composto benzazepina

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160729